Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has added a sixth global site that will augment cGMP manufacturing capacity for mammalian biologics. This expansion is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas.    The new facility will be based in the U.S. and will accommodate phase 3 and commercial manufacturing. A phased approach to c...